The supplied collection links two 510(k) records to Elucid Bioimaging, Inc., both decided Substantially Equivalent in September 2026. The record sample lists Elucid FFR-IQ (B.1) under K262015 and Elucid PlaqueIQ under K261855. The two filings sit in different product codes and advisory committees, so they document separate device identities rather than one submission described twice. [1][2][5]
FFR-IQ and the coronary simulation pathway
K262015 covers Elucid FFR-IQ (B.1), a Traditional 510(k) received June 15, 2026 and decided September 29, 2026. The FDA record lists product code PJA, regulation 21 CFR 870.1415, device class II, and the Cardiovascular advisory committee. The clearance letter identifies the regulation name as Coronary Vascular Physiologic Simulation Software and records the applicant as Elucid Bioimaging, Inc. of Boston, Massachusetts. [1][3]
The same letter states that cybersecurity work was conducted and documented as recommended in FDA guidance on cybersecurity in medical devices. The premarket notification page for K262015 lists the submission as Traditional, not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan. [3][4]
PlaqueIQ and the radiological image-processing pathway
K261855 covers Elucid PlaqueIQ, received June 3, 2026 and decided September 18, 2026. The FDA record lists product code LLZ, regulation 21 CFR 892.2050, device class II, and the Radiology advisory committee. The clearance letter names the regulation as Medical Image Management And Processing System and records Elucid Bioimaging, Inc. at the same Boston address. [2][5]
The letter describes the device as similar to its predicate: a non-invasive application that processes, reviews and analyzes CT images using a semi-automated tool to aid in diagnosis of coronary artery diseases, with output of plaque identification and quantification. [5]
How the company describes its products
Elucid's own announcement of the FFR-IQ clearance describes FFR-IQ as software for noninvasive estimation of fractional flow reserve from coronary CT angiography, and describes the company as an innovator of AI-powered cardiovascular imaging software. The announcement is dated October 21, 2026 and is published by Elucid. [6]
Elucid's healthcare-professional page describes Plaque-IQ as an FDA-cleared plaque assessment tool powered by CT Virtual Histology, trained and validated on ground-truth histology, and indicated for use in the coronary and carotid arteries. The company's about page states that it develops AI to see invisible features of cardiovascular risk and a clinical platform for CCTA-guided care. These are company statements, not FDA findings. [9][10]
What the supplied filings do and do not establish
The collection counts two 510(k) records, both with decision code SESE, and the record sample contains the same two entries. These counts describe the supplied filings as of the snapshot date; they are not measures of total company sales, total portfolio or safety performance. No recall records appear in the public information. [1][2]
The filings establish the applicant identity, device names, product codes, regulation numbers, review committees and decision dates. They do not establish ownership by a parent company, headquarters location, customer base, pricing or commercial availability. The Boston address appears in FDA correspondence and company contact text; it is not treated here as a verified headquarters. [3][5][6]


